Suppr超能文献

基于血浆的实时聚合酶链反应分析检测结直肠癌患者的微卫星不稳定性

Detection of Microsatellite Instability in Colorectal Cancer Patients With a Plasma-Based Real-Time PCR Analysis.

作者信息

Kim Namjoo, Kim Sung Min, Lee Beom Jae, Choi Byung Il, Yoon Hee Sook, Kang Sang Hee, Kim Seung Han, Joo Moon Kyung, Park Jong-Jae, Kim Chungyeul

机构信息

Department of Gastroenterology, Korea University Guro Hospital, Seoul, South Korea.

Department of Surgery, Korea University Guro Hospital, Seoul, South Korea.

出版信息

Front Pharmacol. 2021 Dec 8;12:758830. doi: 10.3389/fphar.2021.758830. eCollection 2021.

Abstract

A microsatellite instability (MSI) test is crucial for screening for HNPCC (Hereditary nonpolyposis colorectal cancer; Lynch syndrome) and optimization of colorectal cancer (CRC) treatment. Mismatch repair (MMR) deficiency is a predictor for good response of immune checkpoint inhibitors in various malignancies. In this study, we evaluated the results of a newly developed plasma-based real-time PCR kit for the detection of MSI in CRC patients. We assessed a peptide nucleotide acid (PNA) probe-mediated real-time PCR test (U-TOP MSI Detection Kit Plus) that determines MSI status by using amplicon melting analysis of five markers (NR21, NR24, NR27, BAT25, and BAT26) from plasma. Eighty-four CRC patients (46 dMMR and 38 pMMR) with colorectal cancer were analyzed. The concordance rate of MSI status assessment between the plasma kit and IHC was 63.0% in dMMR patients (29/46), but in the pMMR evaluation, a 100% (38/38) concordance rate was observed. In the evaluation of the performance of a custom tissue U-TOP MSI Detection Kit and plasma kit in 28 patients, sensitivity, specificity, PPV (positive predictive value) and NPV (negative predictive value) of plasma kit were 68.4, 100, 100, and 44.4%, respectively, with the tissue U-TOP MSI Detection Kit. Our results demonstrate the feasibility of a non-invasive and rapid plasma-based real-time PCR kit (U-TOP MSI Detection Kit Plus) for the detection of MSI in colorectal cancer.

摘要

微卫星不稳定性(MSI)检测对于筛查遗传性非息肉病性结直肠癌(HNPCC;林奇综合征)以及优化结直肠癌(CRC)治疗至关重要。错配修复(MMR)缺陷是各种恶性肿瘤中免疫检查点抑制剂良好反应的预测指标。在本研究中,我们评估了一种新开发的基于血浆的实时PCR试剂盒用于检测CRC患者MSI的结果。我们评估了一种肽核酸(PNA)探针介导的实时PCR检测(U-TOP MSI检测试剂盒升级版),该检测通过对血浆中五个标志物(NR21、NR24、NR27、BAT25和BAT26)的扩增子熔解分析来确定MSI状态。对84例结直肠癌患者(46例错配修复缺陷(dMMR)和38例错配修复正常(pMMR))进行了分析。在dMMR患者中,血浆试剂盒与免疫组化(IHC)之间MSI状态评估的一致性率为63.0%(29/46),但在pMMR评估中,观察到一致性率为100%(38/38)。在对28例患者的定制组织U-TOP MSI检测试剂盒和血浆试剂盒性能的评估中,血浆试剂盒的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)分别为68.4%、100%、100%和44.4%(与组织U-TOP MSI检测试剂盒相比)。我们的结果证明了一种基于血浆的非侵入性快速实时PCR试剂盒(U-TOP MSI检测试剂盒升级版)用于检测结直肠癌MSI的可行性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a42/8694627/8df3ca003e09/fphar-12-758830-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验